Anti-epidermal growth factor receptor regulatory update

IMCL received notice of allowance for a U.S. patent covering the combination of monoclonal antibodies that inhibit the binding of EGF to its receptor and anti-neoplastic agents, and use of the combination to treat cancer. IMCL's IMC-C225 anti-EGFr antibody is in Phase III testing to treat head and neck cancer in combination with radiotherapy or chemotherapy. ...